Enovis [ENOV] vs Conmed [CNMD] Detailed Stock Comparison
Enovis
NYSE
Loading...
Conmed
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Enovis wins in 9 metrics, Conmed wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Enovis | Conmed | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.91 | 14.42 | Enovis |
| Price-to-Book Ratio | 0.62 | 1.58 | Enovis |
| Debt-to-Equity Ratio | 55.68 | 87.93 | Enovis |
| PEG Ratio | 9.03 | 10.55 | Enovis |
| EV/EBITDA | 8.95 | 11.38 | Enovis |
| Profit Margin (TTM) | -37.65% | 8.31% | Conmed |
| Operating Margin (TTM) | -5.50% | 10.62% | Conmed |
| EBITDA Margin (TTM) | N/A | 10.62% | N/A |
| Return on Equity | -27.35% | 11.69% | Conmed |
| Return on Assets (TTM) | 0.49% | 4.03% | Conmed |
| Free Cash Flow (TTM) | $-67.21M | $153.88M | Conmed |
| Dividend Yield | N/A | 1.15% | N/A |
| 1-Year Return | -34.29% | -20.41% | Conmed |
| Price-to-Sales Ratio (TTM) | 0.76 | 1.19 | Enovis |
| Enterprise Value | $2.89B | $2.50B | Enovis |
| EV/Revenue Ratio | 1.35 | 1.89 | Enovis |
| Gross Profit Margin (TTM) | 59.45% | 55.01% | Enovis |
| Revenue per Share (TTM) | $39 | $43 | Conmed |
| Earnings per Share (Diluted) | $-14.64 | $3.54 | Conmed |
| Beta (Stock Volatility) | 1.81 | 1.17 | Conmed |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Enovis vs Conmed Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Enovis | -0.21% | 6.42% | -13.63% | -16.71% | -35.18% | -35.62% |
| Conmed | 2.44% | 4.36% | 2.79% | -4.70% | -19.64% | -20.74% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Enovis | -34.29% | -52.34% | -52.03% | -57.98% | 33.71% | -19.16% |
| Conmed | -20.41% | -48.25% | -37.31% | -4.80% | 171.79% | 83.88% |
Performance & Financial Health Analysis: Enovis vs Conmed
| Metric | ENOV | CNMD |
|---|---|---|
| Market Information | ||
| Market Cap | $1.63B | $1.58B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,338,293 | 560,860 |
| 90 Day Avg. Volume | 1,718,024 | 501,800 |
| Last Close | $28.46 | $54.68 |
| 52 Week Range | $25.47 - $49.83 | $46.00 - $78.19 |
| % from 52W High | -42.89% | -30.07% |
| All-Time High | $129.72 (Jun 09, 2014) | $159.11 (Nov 01, 2021) |
| % from All-Time High | -78.06% | -65.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.03% |
| Quarterly Earnings Growth | 0.08% | -0.29% |
| Financial Health | ||
| Profit Margin (TTM) | -0.38% | 0.08% |
| Operating Margin (TTM) | -0.06% | 0.11% |
| Return on Equity (TTM) | -0.27% | 0.12% |
| Debt to Equity (MRQ) | 55.68 | 87.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $45.83 | $32.41 |
| Cash per Share (MRQ) | $0.67 | $1.10 |
| Operating Cash Flow (TTM) | $148.06M | $165.21M |
| Levered Free Cash Flow (TTM) | $-63,732,752 | $163.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.15% |
| Last 12-Month Dividend | $0.00 | $0.60 |
Valuation & Enterprise Metrics Analysis: Enovis vs Conmed
| Metric | ENOV | CNMD |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.91 | 14.42 |
| Forward P/E | 9.03 | 10.55 |
| PEG Ratio | 9.03 | 10.55 |
| Price to Sales (TTM) | 0.76 | 1.19 |
| Price to Book (MRQ) | 0.62 | 1.58 |
| Market Capitalization | ||
| Market Capitalization | $1.63B | $1.58B |
| Enterprise Value | $2.89B | $2.50B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.35 | 1.89 |
| Enterprise to EBITDA | 8.95 | 11.38 |
| Risk & Other Metrics | ||
| Beta | 1.81 | 1.17 |
| Book Value per Share (MRQ) | $45.83 | $32.41 |
Financial Statements Comparison: Enovis vs Conmed
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ENOV | CNMD |
|---|---|---|
| Revenue/Sales | $558.83M | $321.26M |
| Cost of Goods Sold | $226.61M | $143.50M |
| Gross Profit | $332.23M | $177.75M |
| Research & Development | $28.53M | $12.95M |
| Operating Income (EBIT) | $-42.91M | $15.96M |
| EBITDA | $27.14M | $34.21M |
| Pre-Tax Income | $-57.35M | $7.67M |
| Income Tax | $-1.77M | $1.64M |
| Net Income (Profit) | $-55.71M | $6.04M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ENOV | CNMD |
|---|---|---|
| Cash & Equivalents | $38.46M | $35.49M |
| Total Current Assets | $1.22B | $639.00M |
| Total Current Liabilities | $477.42M | $283.15M |
| Long-Term Debt | $1.42B | $891.44M |
| Total Shareholders Equity | $2.62B | $977.64M |
| Retained Earnings | $-338.99M | $560.13M |
| Property, Plant & Equipment | $492.24M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ENOV | CNMD |
|---|---|---|
| Operating Cash Flow | $-1.07M | $49.72M |
| Capital Expenditures | $-43.26M | $-3.78M |
| Free Cash Flow | $-44.86M | $37.76M |
| Debt Repayment | $-15.44M | $-180.59M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ENOV | CNMD |
|---|---|---|
| Shares Short | 7.43M | 2.11M |
| Short Ratio | 4.68 | 4.86 |
| Short % of Float | 0.20% | 0.09% |
| Average Daily Volume (10 Day) | 1,338,293 | 560,860 |
| Average Daily Volume (90 Day) | 1,718,024 | 501,800 |
| Shares Outstanding | 55.88M | 30.90M |
| Float Shares | 56.40M | 30.68M |
| % Held by Insiders | 0.02% | 0.01% |
| % Held by Institutions | 1.07% | 1.17% |
Dividend Analysis & Yield Comparison: Enovis vs Conmed
| Metric | ENOV | CNMD |
|---|---|---|
| Last 12-Month Dividend | $0.00 | $0.60 |
| Last 12-Month Dividend Yield | N/A | 1.15% |
| 3-Year Avg Annual Dividend | $0.00 | $0.73 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | $0.00 | $2.20 |
| Ex-Dividend Date | N/A | Mar 14, 2025 |